Karyopharm Therapeutics stock analysis
Karyopharm Therapeutics (KPTI) Stock Price & Analysis
KPTI Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 483.43K
- Enterprise Value
- CHF 473.81M
- Total Cash (Recent Filing)
- CHF 65.11M
- Total Debt (Recent Filing)
- CHF 215.88M
- Price to Earnings (P/E)
- 0.0
- Beta
- N/A
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory Progress
Strong Phase III efficacy and constructive FDA feedback support a potentially meaningful expansion of selinexor into myelofibrosis. An on-track sNDA could broaden the commercial franchise, strengthen the company’s clinical position, and create a durable growth opportunity if approval follows.
Established Commercial Platform
Existing XPOVIO sales, an experienced hematology platform, patient support infrastructure, and reaffirmed guidance provide a commercial foundation while pipeline programs advance. Stable product revenue can support market access and launch preparation, even before any new indication contributes materially.
Operating Expense Discipline
Lower R&D and SG&A spending indicates management is prioritizing higher-value programs and improving underlying operating efficiency. If maintained, this discipline can extend the usefulness of existing resources, reduce avoidable cash consumption, and focus investment on the most valuable growth opportunities.
Bears Say
Stressed Balance Sheet And Financing Dependence
Deeply negative equity and debt that is large relative to the asset base leave limited financial flexibility. The capital structure increases dependence on refinancing, new funding, or other strategic transactions, while potential dilution or restrictive financing terms could weigh on future shareholder value.
Persistent Cash Burn And Large Losses
The business is not yet self-funding, with ongoing operating cash outflows and substantial net losses despite some improvement in burn. Continued cash consumption can constrain investment in the pipeline and make the company increasingly dependent on financing until revenue growth or profitability improves.
Pipeline Concentration And Approval Uncertainty
The failed endometrial cancer study reduces diversification across the development pipeline and places greater importance on myelofibrosis execution. Even with encouraging SENTRY results, approval and long-term label confirmation depend on regulatory review and future overall survival evidence.
Karyopharm Therapeutics News
KPTI FAQ
What is Karyopharm Therapeutics’s market cap?
When is Karyopharm Therapeutics’s upcoming earnings report date?
How were Karyopharm Therapeutics’s earnings last quarter?
Is Karyopharm Therapeutics overvalued?
Does Karyopharm Therapeutics pay dividends?
What is Karyopharm Therapeutics’s EPS estimate?
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard A. Paulson
- Employees
- 228
- Website
- www.karyopharm.com
- Address
- 85 Wells Avenue, Newton, MA, 02459-3298, US
Karyopharm Therapeutics (KPTI) Earnings & Revenues
KPTI Company Deck
KPTI Earnings Call
Earnings Call SentimentNeutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.
View all CH:KPTI earnings summaries













